You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

296 Results
Document
This hub contains tools and resources for primary care providers, colposcopists and other health care providers. This material supports the Ontario...
Guidelines and Advice
Status: Current
Version: 1
Updated
Nov 2025
Drug
Other Name(s): Voranigo™
New
Mar 2026
Regimen
Cancer Type:
Central Nervous System
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Updated
Mar 2026

Pages